Non-small Cell Lung Cancer
Conditions
Keywords
Recurrent, previously treated, locally advanced or metastatic NSCLC (non small cell lung cancer)
Brief summary
A Phase 1b study for participants with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) to participate in 1 of 2 portions of this study. The first portion is Dose Escalation in which participants are tested with PEGPH20 at various doses (1.6, 3.0, 2.2 and 2.8 micrograms/kilogram (ug/kg)) in addition to dosing with the standard dose of docetaxel (PDoc) of 75 milligrams/meter squared (mg/m\^2) once every 21-day cycle. Based on observations on the safety and tolerability of study treatment from dose escalation cohorts dosed to date (1.6 and 3.0 ug/kg of PEGPH20), two additional dose levels will be tested, 2.2 and 2.8 ug/kg. Up to 30 additional participants may be enrolled to test these dose levels. The second portion of Phase 1b is Cohort Expansion in which the recommended Phase 2 dose (RP2D) of PDoc identified in dose escalation is administered every 21 days to approximately 50 participants with high hyaluronan (HA-high) prospectively measured in their tumor tissue.
Interventions
DRUGDocetaxel
Sponsors
Halozyme Therapeutics
Study design
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
The study was planned to include a Dose Escalation portion utilizing a standard 3 + 3 dose escalation design. Participants were enrolled sequentially into their assigned dose cohort. The Treatment Period consisted of 21-day treatment cycles with administration of PEGPH20 on Day 1 (doses tested were 1.6, 3.0, and 2.2 ug/kg) and docetaxel (standard dosing 75 mg/m\^2 for all participants) on Day 2 of each cycle.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed, approved Informed Consent. * Histologically confirmed and documented previously treated Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC), having failed 1 previous platinum chemo regimen for locally advanced or metastatic disease. * Cohort Expansion: Available archival tumor tissue block or 5-10 unstained, consecutive core biopsy slides from one archival tumor block that meet specific tissue requirements. * Cohort Expansion: Participants must be determined to be hyaluronidase (HA)-high based on tumor biopsy that meets the requirements noted in the previous inclusion criterion. * Cohort Expansion: One or more tumors measurable on computed tomography/magnetic resonance imaging (CT/MRI) scan per Response Evaluation Criteria on Solid Tumors (RECIST) v 1.1 (Eisenhauer 2009; Appendix C). * Participants may have failed a programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1) therapy for advanced disease. * Participants that are known to be epidermal growth factor (EGFR)-activating mutation positive must have received an EGFR inhibitor. * Participants known to be anaplastic lymphoma kinase (ALK)-fusion/rearrangement mutation positive must have received an ALK inhibitor. * Most prior therapies and prior targeted therapy are allowed and these specific therapies are detailed in the protocol. * Life expectancy - =/\> 3 months, Eastern Cooperative Oncology Group status = 0 or 1. * Negative urine or serum pregnancy test within 7 days before Day 1 (first dose of study medication) if female participants is of childbearing potential (WOCBP). * Men and women agreement to use effective contraceptive method. For WOCBP and for men, agreement to use an effective contraceptive method from the time of screening throughout the study until 1 month for WOCBP or 6 months for men after administration of the last dose of any study medication. * Specific ranges/levels of Screening labs that are acceptable per protocol. * Age \>/= 18 years.
Exclusion criteria
* Previous treatment with docetaxel. * Failed more than 3 treatment regimens for locally advanced or metastatic NSCLC. * New York Heart Assoc Class III or IV cardiac disease, myocardial infarction within the past 12 months before screening, or pre-existing atrial fibrillation. * History of cerebrovascular accident or transient ischemic attack. * Pre-existing carotid artery disease. * Previous history of pulmonary embolism or pulmonary embolism found on screening exam. * No ongoing requirement for corticosteroids * Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy at time of screening. * Known infection with HIV and active infection with hepatitis B or C. * Known allergy to hyaluronidase or any constituents of docetaxel formulation. * Current use (within 10 days of day 1) of megestrol acetate. * Chronic concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole). * Women currently pregnant or breast feeding. * Intolerance to dexamethasone, as determined by Investigator. * History of another primary cancer within the last 3 years that required treatment, with the exception of non-melanoma skin cancer, early stage prostate cancer, or curatively treated cervical carcinoma in situ. * Any other disease, metabolic dysfunction, physical exam finding, or clinical lab finding that leads to reasonable suspicion of disease that contraindicates the use of an investigational drug that might affect interpretation of results or render subject at high risk for treatment complications. * In opinion of Investigator, make subject unsuitable for study. * Hypersensitivity to the active substance or ingredients of PEGPH20 and docetaxel. * Subject's inability to comply with study and follow-up procedures, as judged by the Investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Dose Limiting Toxicities (DLTs) | Cycle 1 (Day 1 through Day 21) (1 Cycle = 21 days) | DLTs were defined as adverse events (AEs) that occurred during Cycle 1 in the Dose Escalation portion of the study, and deemed by the Investigator as related to study treatment. |
| Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | From date of first dose until 30 days after the last dose of study treatment, up to approximately 1 year 10 months | Throughout the Treatment Period, the assessment of safety was based on AEs, including deaths, non-serious AEs, and serious adverse events, AEs leading to discontinuation of study treatment, and results of vital sign measurements and clinical laboratory assessments (including hematology, clinical chemistry, coagulation parameters, and urinalysis). Additionally, thromboembolic (TE) events were deemed by the Sponsor as AEs of special interest. AEs and laboratory values were graded for severity using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. |
| Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of PEGPH20 | Cycle 1 of Dose Escalation portion (Cycle 1 = 21 days) | — |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Phase 1b: Terminal Half-life (t1/2) of PEGPH20 and Docetaxel | PEGPH20: multiple time points C1D1 and all subsequent Cycles; Docetaxel: multiple time points C1D2, C2D2 and C3D2 | Blood samples were collected from all participants per protocol and analyzed for plasma PEGPH20 concentration using a validated ECL immunoassay. Plasma docetaxel concentrations were analyzed using a validated liquid chromatography with LS-MS/MS. The following blood draw schedule was used, PEGPH20: C1D1 (predose, 15 min, 1, 2 to 4, and 24 hr postdose), C2 and all subsequent Cycles (predose, 1 hr postdose). Docetaxel: C1D2 (30 min after the start of the 1-hr infusion, 30 min post completion of the infusion, 4 to 6 and 24 hr post infusion), C1D3 (24 hr post infusion), C2D2 and C3D2 (30 min after the start of the 1-hour infusion, 30 min post completion of the infusion). |
| Phase 1b: Area Under the Plasma Concentration-Time Curve for PEGPH20 and Docetaxel | PEGPH20: multiple time points C1D1 and all subsequent Cycles; Docetaxel: multiple time points C1D2, C2D2 and C3D2 | Blood samples were collected from all participants per protocol and analyzed for plasma PEGPH20 concentration using a validated ECL immunoassay. Plasma docetaxel concentrations were analyzed using a validated liquid chromatography with LS-MS/MS. The following blood draw schedule was used, PEGPH20: C1D1 (predose, 15 min, 1, 2 to 4, and 24 hr postdose), C2 and all subsequent Cycles (predose, 1 hr postdose). Docetaxel: C1D2 (30 min after the start of the 1-hr infusion, 30 min post completion of the infusion, 4 to 6 and 24 hr post infusion), C1D3 (24 hr post infusion), C2D2 and C3D2 (30 min after the start of the 1-hour infusion, 30 min post completion of the infusion). |
| Phase 1b: Volume of Distribution (Vd) of PEGPH20 and Docetaxel | PEGPH20: multiple time points C1D1 and all subsequent Cycles; Docetaxel: multiple time points C1D2, C2D2 and C3D2 | Blood samples were collected from all participants per protocol and analyzed for plasma PEGPH20 concentration using a validated ECL immunoassay. Plasma docetaxel concentrations were analyzed using a validated liquid chromatography with LS-MS/MS. The following blood draw schedule was used, PEGPH20: C1D1 (predose, 15 min, 1, 2 to 4, and 24 hr postdose), C2 and all subsequent Cycles (predose, 1 hr postdose). Docetaxel: C1D2 (30 min after the start of the 1-hr infusion, 30 min post completion of the infusion, 4 to 6 and 24 hr post infusion), C1D3 (24 hr post infusion), C2D2 and C3D2 (30 min after the start of the 1-hour infusion, 30 min post completion of the infusion). |
| Phase 1b: Clearance (CL) of PEGPH20 and Docetaxel | PEGPH20: multiple time points C1D1 and all subsequent Cycles; Docetaxel: multiple time points C1D2, C2D2 and C3D2 | Blood samples were collected from all participants per protocol and analyzed for plasma PEGPH20 concentration using a validated ECL immunoassay. Plasma docetaxel concentrations were analyzed using a validated liquid chromatography with LS-MS/MS. The following blood draw schedule was used, PEGPH20: C1D1 (predose, 15 min, 1, 2 to 4, and 24 hr postdose), C2 and all subsequent Cycles (predose, 1 hr postdose). Docetaxel: C1D2 (30 min after the start of the 1-hr infusion, 30 min post completion of the infusion, 4 to 6 and 24 hr post infusion), C1D3 (24 hr post infusion), C2D2 and C3D2 (30 min after the start of the 1-hour infusion, 30 min post completion of the infusion). |
| Phase 1b: Maximum Plasma Concentration (Cmax) of PEGPH20 and Docetaxel | PEGPH20: multiple time points C1D1 and all subsequent Cycles; Docetaxel: multiple time points C1D2, C2D2 and C3D2 | Blood samples were collected from all participants per protocol and analyzed for plasma PEGPH20 concentration using a validated electrochemiluminescence (ECL) immunoassay. Plasma docetaxel concentrations were analyzed using a validated liquid chromatography with tandem mass spectrometry assay (LS-MS/MS). The following blood draw schedule was used, PEGPH20: Cycle 1 Day 1 (C1D1) (predose, 15 minutes (min), 1, 2 to 4, and 24 hours (hr) postdose), C2 and all subsequent Cycles (predose, 1 hr postdose). Docetaxel: C1D2 (30 min after the start of the 1-hr infusion, 30 min post completion of the infusion, 4 to 6 and 24 hr post infusion), C1D3 (24 hr post infusion), C2D2 and C3D2 (30 min after the start of the 1-hour infusion, 30 min post completion of the infusion). |
| Disease Control Rate (DCR) | From date of treatment start until disease progression or up to data cutoff date (30 Nov 2016), for up to approximately 1 year 9 months | — |
| Duration of Response (DoR) | From date of first CR or PR until the date of first documentation of disease progression or date of death, assessed up to data cutoff date (30 Nov 2016) | — |
| Progression-free Survival (PFS) | From date of treatment start until date of first documentation of progressive disease or death from any cause, assessed up to 1 year 9 months | — |
| Objective Response Rate (ORR) | From date of treatment start until disease progression or up to data cutoff date (30 Nov 2016), for up to approximately 1 year 9 months | ORR = complete response + partial response (CR + PR) |
| Phase 1b: Minimum Plasma Concentration (Cmin) of PEGPH20 and Docetaxel | PEGPH20: multiple time points C1D1 and all subsequent Cycles; Docetaxel: multiple time points C1D2, C2D2 and C3D2 | Blood samples were collected from all participants per protocol and analyzed for plasma PEGPH20 concentration using a validated ECL immunoassay. Plasma docetaxel concentrations were analyzed using a validated liquid chromatography with LS-MS/MS. The following blood draw schedule was used, PEGPH20: C1D1 (predose, 15 min, 1, 2 to 4, and 24 hr postdose), C2 and all subsequent Cycles (predose, 1 hr postdose). Docetaxel: C1D2 (30 min after the start of the 1-hr infusion, 30 min post completion of the infusion, 4 to 6 and 24 hr post infusion), C1D3 (24 hr post infusion), C2D2 and C3D2 (30 min after the start of the 1-hour infusion, 30 min post completion of the infusion). |
| Phase 1b: Time to Maximum Plasma Concentration (Tmax) of PEGPH20 and Docetaxel | PEGPH20: multiple time points C1D1 and all subsequent Cycles; Docetaxel: multiple time points C1D2, C2D2 and C3D2 | Blood samples were collected from all participants per protocol and analyzed for plasma PEGPH20 concentration using a validated ECL immunoassay. Plasma docetaxel concentrations were analyzed using a validated liquid chromatography with LS-MS/MS. The following blood draw schedule was used, PEGPH20: C1D1 (predose, 15 min, 1, 2 to 4, and 24 hr postdose), C2 and all subsequent Cycles (predose, 1 hr postdose). Docetaxel: C1D2 (30 min after the start of the 1-hr infusion, 30 min post completion of the infusion, 4 to 6 and 24 hr post infusion), C1D3 (24 hr post infusion), C2D2 and C3D2 (30 min after the start of the 1-hour infusion, 30 min post completion of the infusion). |
Countries
United States
Participant flow
Pre-assignment details
A total of 16 participants were enrolled, of whom 1 participant was not treated due to disease progression prior to treatment and 15 participants received study treatment.
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1: 1.6 ug/kg PEGPH20 + Docetaxel 1.6 micrograms/kilograms (ug/kg) PEGylated recombinant human hyaluronidase PH20 (PEGPH20) was administered on Day 1 of each 21-day cycle (every 3 weeks) as an intravenous (IV)-infusion over 10 minutes, approximately 1 milliliter/minute (mL/min) (a window of +2 minutes allowed, i.e., infusion could be 10 to 12 minutes). Docetaxel (75 milligrams/meter squared (mg/m\^2)) was administered as an IV-infusion on Day 2 of each 21-day cycle. | 7 |
| Cohort 2: 3.0 ug/kg PEGPH20 + Docetaxel 3.0 ug/kg PEGPH20 was administered on Day 1 of each 21-day cycle (every 3 weeks) as an IV-infusion over 10 minutes, approximately 1 mL/min (a window of +2 minutes allowed, i.e., infusion could be 10 to 12 minutes). Docetaxel (75 mg/m\^2) was administered as an IV-infusion on Day 2 of each 21-day cycle. | 4 |
| Cohort 3: 2.2 ug/kg PEGPH20 + Docetaxel 2.2 ug/kg PEGPH20 was administered on Day 1 of each 21-day cycle (every 3 weeks) as an IV-infusion over 10 minutes, approximately 1 mL/min (a window of +2 minutes allowed, i.e., infusion could be 10 to 12 minutes). Docetaxel (75 mg/m\^2) was administered as an IV-infusion on Day 2 of each 21-day cycle. | 4 |
| Total | 15 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Death | 1 | 3 | 1 |
| Overall Study | Not treated | 1 | 0 | 0 |
| Overall Study | Physician Decision | 0 | 1 | 0 |
| Overall Study | Radiologic progression | 0 | 0 | 1 |
| Overall Study | Sponsor discontinued study | 5 | 0 | 2 |
| Overall Study | Withdrawal of consent | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | Cohort 1: 1.6 ug/kg PEGPH20 + Docetaxel | Cohort 2: 3.0 ug/kg PEGPH20 + Docetaxel | Cohort 3: 2.2 ug/kg PEGPH20 + Docetaxel | Total |
|---|---|---|---|---|
| Age, Continuous | 63.7 years STANDARD_DEVIATION 8.9 | 57.8 years STANDARD_DEVIATION 10.53 | 65.5 years STANDARD_DEVIATION 8.1 | 62.6 years STANDARD_DEVIATION 9.03 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 7 Participants | 3 Participants | 4 Participants | 14 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 6 Participants | 2 Participants | 3 Participants | 11 Participants |
| Sex: Female, Male Female | 6 Participants | 2 Participants | 2 Participants | 10 Participants |
| Sex: Female, Male Male | 1 Participants | 2 Participants | 2 Participants | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 1 / 7 | 3 / 4 | 1 / 4 |
| other Total, other adverse events | 7 / 7 | 4 / 4 | 4 / 4 |
| serious Total, serious adverse events | 3 / 7 | 3 / 4 | 1 / 4 |
Outcome results
Primary
Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of PEGPH20
Time frame: Cycle 1 of Dose Escalation portion (Cycle 1 = 21 days)
Population: The MTD and RP2D were not established due to early study discontinuation.
Primary
Number of Dose Limiting Toxicities (DLTs)
DLTs were defined as adverse events (AEs) that occurred during Cycle 1 in the Dose Escalation portion of the study, and deemed by the Investigator as related to study treatment.
Time frame: Cycle 1 (Day 1 through Day 21) (1 Cycle = 21 days)
Population: The DLT-Evaluable population included all participants who received a full dose of study treatment and completed the initial 21 days of the study after the first dose or who experienced a DLT within the initial 21 days after the first dose and discontinued from the study (if they received a full dose of study drug).
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Cohort 1: 1.6 ug/kg PEGPH20 + Docetaxel | Number of Dose Limiting Toxicities (DLTs) | Deep vein thrombosis | 0 DLTs |
| Cohort 1: 1.6 ug/kg PEGPH20 + Docetaxel | Number of Dose Limiting Toxicities (DLTs) | Sepsis | 0 DLTs |
| Cohort 1: 1.6 ug/kg PEGPH20 + Docetaxel | Number of Dose Limiting Toxicities (DLTs) | Gastroenteritis Escherichia coli | 0 DLTs |
| Cohort 1: 1.6 ug/kg PEGPH20 + Docetaxel | Number of Dose Limiting Toxicities (DLTs) | Neutropenia | 0 DLTs |
| Cohort 2: 3.0 ug/kg PEGPH20 + Docetaxel | Number of Dose Limiting Toxicities (DLTs) | Gastroenteritis Escherichia coli | 1 DLTs |
| Cohort 2: 3.0 ug/kg PEGPH20 + Docetaxel | Number of Dose Limiting Toxicities (DLTs) | Deep vein thrombosis | 1 DLTs |
| Cohort 2: 3.0 ug/kg PEGPH20 + Docetaxel | Number of Dose Limiting Toxicities (DLTs) | Neutropenia | 1 DLTs |
| Cohort 2: 3.0 ug/kg PEGPH20 + Docetaxel | Number of Dose Limiting Toxicities (DLTs) | Sepsis | 1 DLTs |
| Cohort 3: 2.2 ug/kg PEGPH20 + Docetaxel | Number of Dose Limiting Toxicities (DLTs) | Deep vein thrombosis | 1 DLTs |
| Cohort 3: 2.2 ug/kg PEGPH20 + Docetaxel | Number of Dose Limiting Toxicities (DLTs) | Neutropenia | 0 DLTs |
| Cohort 3: 2.2 ug/kg PEGPH20 + Docetaxel | Number of Dose Limiting Toxicities (DLTs) | Sepsis | 0 DLTs |
| Cohort 3: 2.2 ug/kg PEGPH20 + Docetaxel | Number of Dose Limiting Toxicities (DLTs) | Gastroenteritis Escherichia coli | 0 DLTs |
Primary
Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel
Throughout the Treatment Period, the assessment of safety was based on AEs, including deaths, non-serious AEs, and serious adverse events, AEs leading to discontinuation of study treatment, and results of vital sign measurements and clinical laboratory assessments (including hematology, clinical chemistry, coagulation parameters, and urinalysis). Additionally, thromboembolic (TE) events were deemed by the Sponsor as AEs of special interest. AEs and laboratory values were graded for severity using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03.
Time frame: From date of first dose until 30 days after the last dose of study treatment, up to approximately 1 year 10 months
Population: Safety population
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1: 1.6 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | PEGPH20-related AEs | 6 Participants |
| Cohort 1: 1.6 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | SAEs | 3 Participants |
| Cohort 1: 1.6 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | AEs with outcome of death | 0 Participants |
| Cohort 1: 1.6 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | AEs greater than or equal to grade 3 | 5 Participants |
| Cohort 1: 1.6 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | AEs leading to discontinuation of study drug | 1 Participants |
| Cohort 1: 1.6 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | Treatment-related SAEs | 1 Participants |
| Cohort 1: 1.6 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | Docetaxel-related AEs | 7 Participants |
| Cohort 2: 3.0 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | AEs with outcome of death | 0 Participants |
| Cohort 2: 3.0 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | AEs greater than or equal to grade 3 | 4 Participants |
| Cohort 2: 3.0 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | PEGPH20-related AEs | 4 Participants |
| Cohort 2: 3.0 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | Docetaxel-related AEs | 4 Participants |
| Cohort 2: 3.0 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | SAEs | 3 Participants |
| Cohort 2: 3.0 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | Treatment-related SAEs | 2 Participants |
| Cohort 2: 3.0 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | AEs leading to discontinuation of study drug | 1 Participants |
| Cohort 3: 2.2 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | SAEs | 1 Participants |
| Cohort 3: 2.2 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | PEGPH20-related AEs | 4 Participants |
| Cohort 3: 2.2 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | AEs leading to discontinuation of study drug | 2 Participants |
| Cohort 3: 2.2 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | Treatment-related SAEs | 1 Participants |
| Cohort 3: 2.2 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | AEs with outcome of death | 0 Participants |
| Cohort 3: 2.2 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | Docetaxel-related AEs | 4 Participants |
| Cohort 3: 2.2 ug/kg PEGPH20 + Docetaxel | Number of Participants With the Indicated Type of Adverse Events for PEGPH20 and Docetaxel | AEs greater than or equal to grade 3 | 3 Participants |
Secondary
Disease Control Rate (DCR)
Time frame: From date of treatment start until disease progression or up to data cutoff date (30 Nov 2016), for up to approximately 1 year 9 months
Population: Due to early discontinuation of the study, DCR was not assessed.
Secondary
Duration of Response (DoR)
Time frame: From date of first CR or PR until the date of first documentation of disease progression or date of death, assessed up to data cutoff date (30 Nov 2016)
Population: Due to early discontinuation of the study, DoR was not assessed.
Secondary
Objective Response Rate (ORR)
ORR = complete response + partial response (CR + PR)
Time frame: From date of treatment start until disease progression or up to data cutoff date (30 Nov 2016), for up to approximately 1 year 9 months
Population: Due to early discontinuation of the study, ORR was not assessed.
Secondary
Phase 1b: Area Under the Plasma Concentration-Time Curve for PEGPH20 and Docetaxel
Blood samples were collected from all participants per protocol and analyzed for plasma PEGPH20 concentration using a validated ECL immunoassay. Plasma docetaxel concentrations were analyzed using a validated liquid chromatography with LS-MS/MS. The following blood draw schedule was used, PEGPH20: C1D1 (predose, 15 min, 1, 2 to 4, and 24 hr postdose), C2 and all subsequent Cycles (predose, 1 hr postdose). Docetaxel: C1D2 (30 min after the start of the 1-hr infusion, 30 min post completion of the infusion, 4 to 6 and 24 hr post infusion), C1D3 (24 hr post infusion), C2D2 and C3D2 (30 min after the start of the 1-hour infusion, 30 min post completion of the infusion).
Time frame: PEGPH20: multiple time points C1D1 and all subsequent Cycles; Docetaxel: multiple time points C1D2, C2D2 and C3D2
Population: Due to early discontinuation of the study, the AUC was not assessed.
Secondary
Phase 1b: Clearance (CL) of PEGPH20 and Docetaxel
Blood samples were collected from all participants per protocol and analyzed for plasma PEGPH20 concentration using a validated ECL immunoassay. Plasma docetaxel concentrations were analyzed using a validated liquid chromatography with LS-MS/MS. The following blood draw schedule was used, PEGPH20: C1D1 (predose, 15 min, 1, 2 to 4, and 24 hr postdose), C2 and all subsequent Cycles (predose, 1 hr postdose). Docetaxel: C1D2 (30 min after the start of the 1-hr infusion, 30 min post completion of the infusion, 4 to 6 and 24 hr post infusion), C1D3 (24 hr post infusion), C2D2 and C3D2 (30 min after the start of the 1-hour infusion, 30 min post completion of the infusion).
Time frame: PEGPH20: multiple time points C1D1 and all subsequent Cycles; Docetaxel: multiple time points C1D2, C2D2 and C3D2
Population: Due to early discontinuation of the study, CL was not assessed.
Secondary
Phase 1b: Maximum Plasma Concentration (Cmax) of PEGPH20 and Docetaxel
Blood samples were collected from all participants per protocol and analyzed for plasma PEGPH20 concentration using a validated electrochemiluminescence (ECL) immunoassay. Plasma docetaxel concentrations were analyzed using a validated liquid chromatography with tandem mass spectrometry assay (LS-MS/MS). The following blood draw schedule was used, PEGPH20: Cycle 1 Day 1 (C1D1) (predose, 15 minutes (min), 1, 2 to 4, and 24 hours (hr) postdose), C2 and all subsequent Cycles (predose, 1 hr postdose). Docetaxel: C1D2 (30 min after the start of the 1-hr infusion, 30 min post completion of the infusion, 4 to 6 and 24 hr post infusion), C1D3 (24 hr post infusion), C2D2 and C3D2 (30 min after the start of the 1-hour infusion, 30 min post completion of the infusion).
Time frame: PEGPH20: multiple time points C1D1 and all subsequent Cycles; Docetaxel: multiple time points C1D2, C2D2 and C3D2
Population: Due to early discontinuation of the study, Cmax was not assessed.
Secondary
Phase 1b: Minimum Plasma Concentration (Cmin) of PEGPH20 and Docetaxel
Blood samples were collected from all participants per protocol and analyzed for plasma PEGPH20 concentration using a validated ECL immunoassay. Plasma docetaxel concentrations were analyzed using a validated liquid chromatography with LS-MS/MS. The following blood draw schedule was used, PEGPH20: C1D1 (predose, 15 min, 1, 2 to 4, and 24 hr postdose), C2 and all subsequent Cycles (predose, 1 hr postdose). Docetaxel: C1D2 (30 min after the start of the 1-hr infusion, 30 min post completion of the infusion, 4 to 6 and 24 hr post infusion), C1D3 (24 hr post infusion), C2D2 and C3D2 (30 min after the start of the 1-hour infusion, 30 min post completion of the infusion).
Time frame: PEGPH20: multiple time points C1D1 and all subsequent Cycles; Docetaxel: multiple time points C1D2, C2D2 and C3D2
Population: Due to early discontinuation of the study, Cmin was not assessed.
Secondary
Phase 1b: Terminal Half-life (t1/2) of PEGPH20 and Docetaxel
Blood samples were collected from all participants per protocol and analyzed for plasma PEGPH20 concentration using a validated ECL immunoassay. Plasma docetaxel concentrations were analyzed using a validated liquid chromatography with LS-MS/MS. The following blood draw schedule was used, PEGPH20: C1D1 (predose, 15 min, 1, 2 to 4, and 24 hr postdose), C2 and all subsequent Cycles (predose, 1 hr postdose). Docetaxel: C1D2 (30 min after the start of the 1-hr infusion, 30 min post completion of the infusion, 4 to 6 and 24 hr post infusion), C1D3 (24 hr post infusion), C2D2 and C3D2 (30 min after the start of the 1-hour infusion, 30 min post completion of the infusion).
Time frame: PEGPH20: multiple time points C1D1 and all subsequent Cycles; Docetaxel: multiple time points C1D2, C2D2 and C3D2
Population: Due to early discontinuation of the study, t1/2 was not assessed.
Secondary
Phase 1b: Time to Maximum Plasma Concentration (Tmax) of PEGPH20 and Docetaxel
Blood samples were collected from all participants per protocol and analyzed for plasma PEGPH20 concentration using a validated ECL immunoassay. Plasma docetaxel concentrations were analyzed using a validated liquid chromatography with LS-MS/MS. The following blood draw schedule was used, PEGPH20: C1D1 (predose, 15 min, 1, 2 to 4, and 24 hr postdose), C2 and all subsequent Cycles (predose, 1 hr postdose). Docetaxel: C1D2 (30 min after the start of the 1-hr infusion, 30 min post completion of the infusion, 4 to 6 and 24 hr post infusion), C1D3 (24 hr post infusion), C2D2 and C3D2 (30 min after the start of the 1-hour infusion, 30 min post completion of the infusion).
Time frame: PEGPH20: multiple time points C1D1 and all subsequent Cycles; Docetaxel: multiple time points C1D2, C2D2 and C3D2
Population: Due to early discontinuation of the study, Tmax was not assessed.
Secondary
Phase 1b: Volume of Distribution (Vd) of PEGPH20 and Docetaxel
Blood samples were collected from all participants per protocol and analyzed for plasma PEGPH20 concentration using a validated ECL immunoassay. Plasma docetaxel concentrations were analyzed using a validated liquid chromatography with LS-MS/MS. The following blood draw schedule was used, PEGPH20: C1D1 (predose, 15 min, 1, 2 to 4, and 24 hr postdose), C2 and all subsequent Cycles (predose, 1 hr postdose). Docetaxel: C1D2 (30 min after the start of the 1-hr infusion, 30 min post completion of the infusion, 4 to 6 and 24 hr post infusion), C1D3 (24 hr post infusion), C2D2 and C3D2 (30 min after the start of the 1-hour infusion, 30 min post completion of the infusion).
Time frame: PEGPH20: multiple time points C1D1 and all subsequent Cycles; Docetaxel: multiple time points C1D2, C2D2 and C3D2
Population: Due to early discontinuation of the study, Vd was not assessed.
Secondary
Progression-free Survival (PFS)
Time frame: From date of treatment start until date of first documentation of progressive disease or death from any cause, assessed up to 1 year 9 months
Population: Due to early discontinuation of the study, PFS was not assessed.